Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 29

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 29
---
j 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 19/44                  
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
| Net financial items |     | $ | 63 |     | $ | 71 |     | $ | 119 |     | $ | 204 |

Interest and Other Financial Income

Interest and other financial income was $58 million in the first six months of 2025 compared to $88 million in the first six months of 2024. The decrease of $30 million was primarily driven by lower average cash and cash equivalents and marketable securities as a result of the ProfoundBio acquisition in the second quarter of 2024, as well as lower interest rates on USD denominated marketable securities in the first six months of 2025 compared to the first six months of 2024.

Gain on Marketable Securities, Net Gain on marketable securities, net, which includes foreign exchange rate movements on marketable securities, was $57 million in the first six months of 2025 compared to $70 million in the first six months of 2024. The decrease in gain on marketable securities, net is primarily driven by the change in functional currency of Genmab A/S on January 1, 2025. As the majority of the investment portfolio is denominated in USD, those securities are no longer impacted by foreign exchange rate fluctuations included in the gain on marketable securities, net.

#### Foreign Exchange Rate Gain, Net
Foreign exchange rate gain, net, which excludes foreign exchange rate movements on marketable securities, was $17 million in the first six months of 2025 compared to foreign exchange rate gain, net of $48 million in the first six months of 2024. The decrease in foreign exchange rate gain, net is primarily driven by a lower foreign exchange rate impact due to the change in functional currency of Genmab A/S from DKK to USD on January 1, 2025.

Refer to Financial Statement Note 1 and Note 6 in this interim report for further details about the net financial items.

Key Developments to Net Financial Items – Second Quarter of 2025

#### Interest and Other Financial Income
Interest and other financial income was $25 million for the second quarter of 2025 compared to $42